Allergic Rhinitis

Introduction

Background

Allergic rhinitis (AR) is an immune-mediated inflammatory response to normally harmless environmental allergens, characterized by symptoms such as sneezing, runny nose, nasal congestion, and itching.^[1]It is often comorbid with other allergic diseases, including asthma, atopic dermatitis, and eczema, highlighting a shared disease pathology.^[1]A distinct condition, non-allergic rhinitis (NAR), presents with similar symptoms but without evidence of allergic sensitization.^[2]For research purposes, allergic rhinitis is typically defined by current symptoms within a specific timeframe (e.g., 12 months) and confirmed allergic sensitization, often through positive specific IgE levels or skin prick tests.^[2]The reliability of allergic rhinitis and sensitization status can vary at younger ages, showing poorer correlation with later life status, hence a lower age limit (e.g., 6 years) is often applied in studies.^[2]

Biological Basis

The biological foundation of allergic rhinitis involves an exaggerated immune response, primarily characterized by type 2 inflammation, which includes B-cell and Th2 responses.^[3]Genetic factors play a substantial role in susceptibility to allergic rhinitis, with numerous risk loci and genetic pathways identified through genome-wide association studies (GWAS).^[4]These studies have also revealed a significant shared genetic architecture between allergic rhinitis and other allergic conditions like asthma and eczema.^[3]Specific genetic variants, known as expression single nucleotide polymorphisms (eSNPs), have been found to be associated with both gene expression and allergic rhinitis, suggesting their involvement in disease pathogenesis.^[4]Research has also implicated mitochondrial pathways in allergic rhinitis pathogenesis.^[4] Furthermore, studies have identified susceptibility loci that are specific to certain ethnicities, underscoring the importance of diverse populations in genetic research. ^[4] For example, the SNP rs60242841 in the LINC00299gene has been associated with progression from atopic dermatitis to asthma and is enriched in individuals of African American ancestry.^[5]

Clinical Relevance

Allergic rhinitis is a common condition with considerable clinical impact. Accurate diagnosis relies on the assessment of symptoms combined with objective evidence of allergic sensitization, such as elevated specific IgE antibodies or positive skin prick test results.^[2]The condition often coexists with asthma, with epidemiological evidence supporting this comorbidity.^[6]The strong pathogenetic link between upper and lower airway diseases suggests that therapeutic strategies targeting the upper airway could potentially yield positive outcomes for allergic rhinitis.^[4]It has also been proposed that allergic rhinitis with concurrent asthma may represent a distinct subphenotype compared to allergic rhinitis without asthma.^[4]

Social Importance

Allergic rhinitis affects a significant portion of the global population and can substantially impact an individual’s quality of life.^[2]The identification of genetic risk factors is crucial for advancing the understanding of disease mechanisms, which could lead to the development of more effective prevention and treatment strategies.^[4]Understanding the shared genetic architecture of allergic rhinitis with other allergic diseases is also vital for comprehending the “allergic march”—the natural progression of allergic conditions over a person’s lifetime.^[5] This knowledge contributes to a more comprehensive approach to managing allergic diseases and improving patient outcomes.

Limitations

Phenotypic Heterogeneity and Measurement Challenges

Allergic rhinitis, as a complex trait, presents inherent challenges in precise phenotypic definition across diverse studies. Diagnostic criteria for the condition can vary, with some research employing commonly accepted criteria while others utilize ICD-10-based disease endpoints that may diverge from current clinical practice.^[4] These inconsistencies, alongside differing phenotypic coding definitions between large cohorts such as FinnGen and UK Biobank, can impact the comparability and interpretation of genetic associations. ^[3]

Many genetic studies incorporate broad allergic symptom phenotypes that combine allergic rhinitis/hay fever with other conditions like eczema, which can obscure whether identified genetic variants are specific to allergic rhinitis or indicate a more general predisposition to allergic diseases.^[6]While these conditions may share underlying physiological mechanisms, analyzing them as a combined phenotype can prevent the identification of disease-specific genetic markers.^[7] Furthermore, reliance on self-reported conditions in large population cohorts, such as the UK Biobank, introduces a potential for misclassification if participants do not accurately report their health status. ^[6]Age-related factors also play a role, as allergic rhinitis and sensitization status show poorer correlation at younger ages, leading some studies to impose lower age limits for participant inclusion to account for transient symptoms or sensitization.^[2] Additionally, recall bias can affect self-reported age-of-onset for allergic diseases, though some studies have addressed this through sensitivity analyses in more homogenous subgroups. ^[8]

Population Specificity and Generalizability

Genetic investigations into allergic rhinitis have revealed that susceptibility loci are often specific to particular ethnicities or ancestries, a pattern consistent with findings in other complex diseases such as asthma and obesity.^[4]For example, some genome-wide association studies (GWAS) have identified genome-wide significant loci unique to Latino populations or demonstrated ethnicity-specific findings even when analyses were stratified by comorbid asthma status.^[4] This highlights the importance of studying diverse populations but also points to limitations in applying findings broadly.

While the utility of studying ancestrally diverse populations is recognized, many large-scale genetic analyses, particularly those utilizing cohorts like the UK Biobank, frequently filter for participants of specific ancestries, such as Caucasian, to mitigate the effects of population stratification. ^[7]This methodological approach, while robust for controlling confounding within a defined group, inherently limits the direct generalizability of identified genetic associations to other ethnic groups and may not fully represent the global genetic architecture of allergic rhinitis. The observed shared genetic architecture within a specific population, such as Caucasians in the UK Biobank, may also differ from cross-population genetic correlations, even for the same disease.^[6]

Methodological and Unexplained Variation

Genetic studies often face inherent limitations related to their design and statistical power. For certain inflammatory upper respiratory disease (IURD) phenotypes, effective sample sizes may be insufficient for robust replication analysis of identified genetic variants, which can increase the risk of false positives if primary findings are not independently confirmed.^[3] Furthermore, phenotypes diagnosed by specialists, often in hospital environments, can be subject to ascertainment bias (collider bias), a study design feature that may artificially inflate correlation estimates with other disorders. ^[3]The presence of shared cases and completely shared controls between asthma and various allergic diseases in large cohorts like the UK Biobank also introduces statistical interdependencies, although some analyses have shown robustness to this overlap.^[6]

Despite substantial progress in identifying genetic risk loci, a significant portion of the population-attributable risk for allergic rhinitis remains unexplained by current genetic findings.^[2]This “missing heritability” suggests that numerous genetic variants with small effects, complex gene-environment interactions, or other unmeasured factors contribute to disease susceptibility and progression.^[4]For instance, while mitochondrial pathways have not been traditionally associated with allergic rhinitis pathogenesis in prior genetic studies, emerging research indicates their potential role, highlighting areas where current understanding is incomplete.^[4]Moreover, the implications of individual single nucleotide polymorphism (SNP) associations in complex traits are often challenging to fully define, underscoring the need for integrated approaches that consider broader biological contexts beyond single variants.^[4]Non-allergic rhinitis, despite its prevalence, also remains a poorly understood disease entity, with initial GWAS efforts failing to identify genome-wide significant risk loci.^[2]

Variants

Genetic variations play a crucial role in an individual’s susceptibility to allergic rhinitis, influencing various aspects of the immune system’s response to allergens. Several single nucleotide polymorphisms (SNPs) across diverse genomic regions have been identified as contributors to the complex genetic architecture of this common allergic condition. These variants often affect genes involved in immune cell signaling, antigen presentation, and inflammatory pathways.

Genes encoding interleukin receptors and Toll-like receptors are central to initiating and modulating immune responses. For instance, variants rs72823641 and rs13020553 are located in or near IL1RL1 and IL18R1, respectively, which encode receptors for interleukin-1 family cytokines crucial in inflammation and Type 2 immune responses fundamental to allergic diseases. Similarly, polymorphisms in Toll-like receptor genes, such as rs5743604 , rs5743618 , and rs66819621 within TLR1, and rs28690449 in the TLR10-TLR1region, can alter innate immune recognition and signaling, thereby influencing the propensity for allergic sensitization and inflammation.^{[2], [9]}The Major Histocompatibility Complex (MHC) region, particularly genes like HLA-DQA1 and HLA-DQB1, is a well-established hotspot for immune-related genetic associations. Variants such as rs28407950 , rs34004019 , and rs7744020 within the HLA-DQA1 - HLA-DQB1region are implicated in allergic rhinitis by affecting antigen presentation, which dictates how the immune system recognizes and responds to specific allergens. Furthermore, theIL7R gene, encoding a receptor vital for lymphocyte development, contains variants like rs6881270 and rs7717955 that can modulate T and B cell function, thereby impacting the adaptive immune response in allergic conditions. ^{[2], [10]}Other loci contributing to allergic rhinitis risk include theCLEC16A gene, where rs12935657 is located, which plays a role in immune regulation and has been linked to various inflammatory diseases. The EMSY - LINC02757 region, encompassing variants like rs7936312 , rs55646091 , and rs11236797 , includes a gene involved in DNA repair (EMSY) and a long non-coding RNA (LINC02757), which can regulate gene expression and immune cell processes. Similarly, genetic variations such as rs1438673 in the WDR36 - RPS3AP21 intergenic region, rs34290285 in D2HGDH, and rs7728912 within the SLC25A46 - BCLAF1P1region are also associated with allergic disease susceptibility, potentially by influencing cellular metabolism, mitochondrial function, or broader immune regulatory networks.^{[5], [11]}## Signs and Symptoms

Key Variants

RS ID	Gene	Related Traits
rs72823641 rs13020553	IL1RL1, IL18R1	asthma asthma, allergic disease childhood onset asthma adult onset asthma allergic rhinitis
rs7936312 rs55646091 rs11236797	EMSY - LINC02757	asthma eosinophil count childhood onset asthma adult onset asthma atopic asthma
rs5743604 rs5743618 rs66819621	TLR1	protein measurement allergic rhinitis
rs28407950 rs34004019 rs7744020	HLA-DQA1 - HLA-DQB1	adult onset asthma childhood onset asthma allergic rhinitis Antihistamine use measurement
rs28690449	TLR10 - TLR1	asthma allergic rhinitis
rs1438673	WDR36 - RPS3AP21	asthma, allergic disease allergic disease asthma, seasonal allergic rhinitis eosinophilic esophagitis atopic eczema
rs34290285	D2HGDH	eosinophil percentage of leukocytes eosinophil count eosinophil percentage of granulocytes asthma, allergic disease basophil count, eosinophil count
rs7728912	SLC25A46 - BCLAF1P1	allergic rhinitis
rs6881270 rs7717955	IL7R	asthma, allergic disease allergic rhinitis multiple sclerosis
rs12935657	CLEC16A	atopic asthma allergic rhinitis asthma childhood onset asthma asthma, age at onset

Clinical Presentation and Symptom Assessment

Allergic rhinitis is primarily characterized by a constellation of upper respiratory symptoms, including sneezing, nasal congestion, rhinorrhea, and nasal itching.^[2] These manifestations reflect an inflammatory response, often occurring within the last 12 months for a current diagnosis. ^[2] Symptom severity can vary widely among individuals, influencing their daily quality of life. ^[12]

Assessment of these symptoms frequently relies on subjective measures, such as self-reports provided through questionnaires or interviews. ^[13]Participants may report a physician diagnosis of allergic rhinitis or hay fever, though inconsistencies between different reporting methods, such as touch-screen questionnaires versus interviews, can occur.^[1] Such self-reported data is crucial for defining clinical phenotypes and understanding the prevalence of the condition. ^[13]

Diagnostic Criteria and Objective Measures

Objective diagnostic confirmation of allergic rhinitis involves identifying allergic sensitization, typically through specific IgE testing or skin prick tests (SPT).^[2] For specific IgE, a level below 0.35 IU/mL is generally considered negative for sensitization, while levels equal to or greater than 0.35 IU/mL, or a higher cut-off of 3.5 IU/mL, can define sensitization depending on the study. ^[2] Similarly, an SPT reaction of less than 1 mm is negative, whereas a reaction of 1 mm or greater, or 3 mm larger than a negative control, indicates sensitization. ^[2]

The diagnostic significance of these objective measures lies in distinguishing allergic rhinitis from non-allergic rhinitis, where individuals experience similar symptoms but lack allergic sensitization.^[2]Cases of allergic rhinitis are defined by the presence of current symptoms within the last 12 months combined with positive specific IgE and/or a positive skin prick test for relevant allergens.^[2] This dual approach, integrating clinical presentation with objective evidence of sensitization, is fundamental for accurate diagnosis and classification. ^[2]

Phenotypic Diversity and Comorbidities

Allergic rhinitis exhibits significant phenotypic diversity and heterogeneity, influenced by factors such as age and comorbidity.^[4]For instance, allergic rhinitis and sensitization status show poorer correlation at younger ages, leading to a lower age limit, typically 6 years, for reliable diagnostic assessment due to transient symptoms or later development of sensitization.^[2] Furthermore, presentation patterns can vary across different ethnic groups, indicating ethnicity-specific susceptibility loci. ^[4]

A critical aspect of allergic rhinitis is its frequent comorbidity with other allergic diseases, particularly asthma and eczema.^[6]The shared genetic architecture and strong link between upper and lower airway disease pathogenesis suggest that allergic rhinitis with comorbid asthma may represent a distinct disease subphenotype.^[6]While self-reported phenotypes sometimes combine allergic rhinitis and eczema, potential misclassification necessitates careful consideration in diagnostic and research settings.^[6]

Causes of Allergic Rhinitis

Allergic rhinitis is a common inflammatory condition of the nasal passages, characterized by an exaggerated immune response to typically harmless environmental allergens.^[1] Its development is influenced by a complex interplay of genetic predispositions, environmental exposures, developmental factors, and the presence of other medical conditions. Understanding these multifaceted causes is crucial for effective management and prevention.

Genetic Predisposition

Allergic rhinitis has a strong heritable component, with numerous inherited genetic variants contributing to an individual’s susceptibility. Genome-wide association studies (GWAS) have identified 41 distinct risk loci associated with allergic rhinitis, which collectively account for a significant portion (39%) of the condition’s prevalence in the general population.^[2]These studies demonstrate that genetic risk scores, derived from these variants, correlate directly with the likelihood of developing allergic rhinitis, with individuals possessing higher scores facing a greater risk.^[2]

Allergic rhinitis is a complex, polygenic trait, meaning it is influenced by the combined effects of multiple genetic polymorphisms rather than single gene mutations.^[4]There is a notable shared genetic architecture across various allergic diseases, including asthma, allergic sensitization, and eczema, suggesting common underlying biological pathways and predisposing factors.^[6]Genetic analyses have highlighted specific pathways, such as those involving B-cell and Th2 immune responses, and have also implicated mitochondrial pathways in the pathogenesis of allergic rhinitis.^[2] Specific genes, like HLA-DQ and RBFOX1, have been identified as susceptibility genes in related allergic conditions, further illustrating the intricate genetic landscape. ^[14]

Environmental Triggers and Exposures

Environmental factors play a critical role in triggering and exacerbating allergic rhinitis symptoms, particularly through exposure to specific allergens. Allergen-specific immunoglobulin E (IgE) is central to the disease mechanism, as it binds to environmental allergens and initiates the immunological cascades that lead to allergic inflammation.^[15] Beyond direct allergen contact, broader environmental exposures, such as air pollution from traffic, have been linked to an increased incidence of respiratory infections and allergic symptoms, especially in children. ^[6]

Socioeconomic factors and geographic location can also influence exposure patterns to various allergens and pollutants, thereby affecting disease prevalence and severity. Furthermore, early life environmental exposures are crucial in shaping immune system development and subsequent susceptibility to allergic rhinitis.^[2] For instance, sensitization status and symptoms in very young children often show a poorer correlation with their status later in life, reflecting the dynamic nature of immune development and the ongoing influence of environmental interactions during childhood. ^[2]

Gene-Environment Interactions and Epigenetic Mechanisms

The development of allergic rhinitis is a result of dynamic interactions between an individual’s genetic makeup and their environment. Genetic predispositions can modify how an individual responds to environmental triggers, creating specific gene-environment interactions that influence disease risk.^[16]For example, specific genetic variants associated with allergic rhinitis have been shown to interact with factors like birth order, highlighting the complex interplay between inherited susceptibility and environmental context.^[16]These interactions underscore that neither genes nor environment act in isolation but rather synergistically contribute to the disease phenotype.

Beyond direct genetic inheritance, epigenetic mechanisms, which involve changes in gene expression without altering the underlying DNA sequence, also contribute to allergic rhinitis. Processes such as DNA methylation and histone modifications can regulate immune-related gene activity, influencing an individual’s allergic responses. An epigenome-wide association study has explored the link between epigenetic changes and total serum immunoglobulin E concentration, a key marker of allergic sensitization, suggesting that these modifications play a role in modulating immune function and disease susceptibility.^[6] Such early life influences and epigenetic programming can have lasting effects on the immune system’s reactivity to allergens.

Modulating Factors and Comorbidities

Allergic rhinitis frequently co-occurs with other allergic and respiratory conditions, reflecting a unified immune system and shared pathogenic mechanisms across the respiratory tract.^[3]There is robust epidemiological evidence demonstrating a strong comorbidity between asthma and rhinitis, with rhinitis often serving as an independent risk factor for both adult-onset asthma and the persistence of asthma into middle age.^[6]The presence of allergic rhinitis with comorbid asthma may even represent a distinct disease subphenotype, influencing its genetic and clinical characteristics.^[4]

Age and biological sex also play significant roles in modulating the manifestation and progression of allergic rhinitis. Age-of-onset information has proven valuable in identifying specific genetic variants associated with allergic diseases, indicating that the timing of symptom development can offer insights into underlying mechanisms.^[8]Additionally, studies have identified gene-sex interactions in allergic rhinitis, suggesting that biological sex can modulate genetic predispositions and influence how the disease presents.^[17]These demographic factors, alongside the presence of other medical conditions, contribute to the complex and variable presentation of allergic rhinitis.

Biological Background

Genetic Predisposition and Regulation

Research indicates that genetic variants are associated with an individual’s susceptibility to allergic rhinitis.^[16] These genetic differences, identified through genome-wide meta-analyses, highlight specific loci that contribute to the development of this condition. ^[16] Such variants can influence various cellular functions and regulatory networks, thereby impacting an individual’s predisposition to allergic responses and their overall immune system regulation. ^[16]

Immune Sensitization and Pathophysiology

Allergic rhinitis is characterized by an immune process of sensitization, exemplified by “grass sensitization,” where the body develops a specific reactivity to environmental allergens.^[16] This sensitization represents a fundamental pathophysiological process where the immune system, upon initial exposure, prepares for an exaggerated response to subsequent allergen encounters. ^[16] The underlying mechanisms involve complex cellular pathways and the coordinated action of various biomolecules that orchestrate the allergic reaction, leading to homeostatic disruptions. ^[16]

Environmental and Developmental Modulators

The manifestation of allergic rhinitis is not solely determined by genetic factors but also by interactions with environmental influences, such as those related to birth order.^[16] These interactions suggest that early-life exposures and developmental processes can modulate the immune system’s maturation and its subsequent reactivity to allergens. ^[16]This interplay between inherited genetic predispositions and external factors highlights the multifaceted etiology of allergic conditions, influencing how and when the disease develops.^[16]

Tissue-Level Effects and Systemic Consequences

Allergic rhinitis primarily affects the nasal mucosa, where localized immune responses lead to characteristic symptoms upon allergen re-exposure.^[16] This organ-specific reaction involves tissue interactions that result in inflammation and the disruption of normal physiological functions within the nasal passages. ^[16] While symptoms are often localized, the systemic nature of the immune system implies that the underlying allergic mechanisms can have broader, though often less overt, systemic consequences throughout the body. ^[16]

Pathways and Mechanisms

Immune Cell Activation and Inflammatory Signaling

Allergic rhinitis involves a complex interplay of immune cell activation and inflammatory signaling pathways. Central to this process is the production of allergen-specificIgE, which plays a pivotal role in initiating allergic reactions and subsequent inflammation. ^[9] The presence of these IgEantibodies against common environmental antigens defines allergic sensitization, a critical step that primes the immune system for an allergic response.^[9]Genetic analyses have revealed an enrichment of pathways involved in Th1 and Th2 Activation, indicating a dysregulation in adaptive immune responses that contributes to the disease.^[2]Specifically, allergic rhinitis is characterized by type 2 inflammation, a hallmark of allergic diseases driven by Th2 cells and their secreted cytokines.^[3]This immune activation triggers intricate intracellular signaling cascades within immune cells, leading to the release of various inflammatory mediators that manifest as the characteristic symptoms of allergic rhinitis.

Genetic Regulation and Molecular Networks

The molecular basis of allergic rhinitis is deeply rooted in genetic regulation and the interactions within complex molecular networks. This includes the identification of expression single nucleotide polymorphisms (eSNPs), which are genetic variants associated with both gene expression levels and allergic rhinitis itself.^[4]Through integrated genome-wide association studies (GWAS) and gene expression profiling, these eSNPs help delineate gene coexpression modules, which represent groups of genes with similar expression patterns that are functionally relevant to allergic rhinitis.^[4] Further regulatory insights come from expression quantitative trait loci (eQTL) and methylation quantitative trait loci (meQTL) analyses, which identify genes whose expression or methylation status is influenced by specific genetic variations. ^[2] These prioritized genes often encode proteins that engage in extensive interactions, forming intricate networks. Several of these interacting proteins, such as TNFSF11, NDUFAF1, PD-L1, IL-5, and IL-13, represent potential therapeutic targets for existing or developing drugs. ^[2]The shared genetic architecture observed between allergic rhinitis and other allergic diseases like asthma further underscores common regulatory pathways and network components.^[6]

Mitochondrial Metabolism and Oxidative Stress

Mitochondrial pathways are significantly enriched in the context of allergic rhinitis, highlighting a critical role for metabolic dysregulation in its pathogenesis.^[4] These perturbations in mitochondrial function directly impact energy metabolism and the generation of reactive oxygen species (ROS), which are vital for maintaining normal acquired immune responses, including the activation of T-cells, differentiation of B-cells, and proliferation of both T-cells and B-cells. ^[4] Consequently, alterations in the acquired immune response, which are frequently observed in allergic inflammation, can be directly linked to disruptions in mitochondrial processes. ^[4] Experimental evidence from models of allergic airway inflammation supports this hypothesis, demonstrating mitochondrial dysfunction characterized by reduced cytochrome c oxidase activity and altered cytosolic distribution of cytochrome c. ^[4]This suggests that precise metabolic regulation and flux control within mitochondria are crucial disease-relevant mechanisms in allergic rhinitis.

Systems-Level Integration and Tissue Dysregulation

Allergic rhinitis manifests as a local condition but is integrated within a broader systems-level context, exemplified by the “unified airway” concept, which describes the strong link between upper (e.g., nasal) and lower (e.g., bronchial) airway disease pathogenesis.^[4]This integration involves extensive pathway crosstalk and complex network interactions across different tissues and cell types. Genetic signals associated with allergic rhinitis are notably enriched in immune cell subsets and various respiratory system tissues, including the oropharynx, respiratory tract, and nasal tissues.^[2]Furthermore, the integrity of the epithelial barrier, maintained by specialized structures like tight junctions, plays a significant role in the development of allergic diseases, with chronic rhinosinusitis sharing common genetic elements with allergic rhinitis.^[18]Dysregulation in these hierarchically regulated and interconnected systems, including processes like epithelium development, can lead to emergent properties of allergic inflammation and increased susceptibility to the disease.^[6]

Clinical Relevance

Diagnosis, Risk Stratification, and Personalized Approaches

Allergic rhinitis is clinically characterized by current rhinitis symptoms coupled with evidence of allergic sensitization, which can be identified through positive specific IgE levels or skin prick tests.^[2]This diagnostic clarity is crucial for distinguishing allergic rhinitis from non-allergic rhinitis, a condition with similar symptoms but lacking allergic sensitization, thereby guiding appropriate management strategies.^[2]Furthermore, research often focuses on individuals aged 6 years and older, as the correlation between allergic rhinitis and sensitization status is less reliable in younger children due to potentially transient symptoms or the ongoing development of sensitization during late childhood.^[2]

Genetic studies contribute significantly to risk stratification, demonstrating that a notable portion of allergic rhinitis prevalence in the general population can be attributed to specific genetic loci, with higher prevalence observed in individuals with elevated genetic risk scores.^[2]These insights allow for the identification of high-risk individuals who could benefit from early intervention or more tailored management plans. The development of personalized medicine approaches is further supported by findings that reveal ethnicity-specific susceptibility loci and distinct genetic architectures for allergic rhinitis with or without comorbid asthma.^[4]This suggests that treatment selection could be optimized based on a patient’s genetic profile and specific disease subphenotype. Moreover, integrating genotype and gene expression data has identified novel biological pathways, such as mitochondrial perturbations, which may serve as new therapeutic targets for allergic rhinitis.^[4]

Comorbidities and Disease Progression

Allergic rhinitis frequently co-occurs with other atopic conditions, forming a component of the “allergic march.” Robust epidemiological evidence confirms a strong comorbidity between rhinitis and asthma, with rhinitis often acting as an independent risk factor for both the onset of adult asthma and general asthma incidence.^[19]Longitudinal studies have shown that childhood allergic rhinitis can predict the incidence and persistence of asthma into middle age.^[20]This strong association is underpinned by a shared genetic architecture between asthma and other allergic diseases, including allergic rhinitis and eczema, all of which are IgE-mediated hypersensitivities involving epithelial cell mechanisms.^[6]The concept of a “unified immune system” highlights the intricate nasobronchial interactions in allergic airway disease, suggesting that interventions targeting the upper airway could also influence lower airway disease pathogenesis.^[21]

The genetic and clinical links between allergic rhinitis and conditions such as asthma and eczema carry important prognostic implications, indicating that individuals with allergic rhinitis may face an increased risk for developing or experiencing more severe forms of these comorbid conditions.^[22]Research suggests that allergic rhinitis accompanied by asthma may constitute a distinct disease subphenotype, impacting both disease progression and responsiveness to treatment.^[4]Furthermore, inflammatory and infectious upper respiratory diseases, including allergic rhinitis, share genetic elements and pathways involving type 2 inflammation, offering a broader biological context for understanding disease mechanisms and potential complications.^[3] A comprehensive understanding of these overlapping phenotypes and genetic correlations is vital for predicting long-term outcomes and developing holistic patient care strategies.

Genetic Architecture and Future Directions in Management

Genome-wide association studies (GWAS) have been instrumental in identifying numerous risk loci and genetic pathways that underpin allergic rhinitis, significantly advancing the understanding of its complex genetic architecture.^[2] These studies have revealed ethnicity-specific findings, underscoring the necessity of including diverse populations in genetic research to capture the full spectrum of susceptibility variants. ^[4]By integrating GWAS data with gene expression analysis and coexpression network approaches, researchers have moved beyond identifying individual single nucleotide polymorphism (SNP) associations to uncover broader biological contexts and novel pathways, such as those involving mitochondrial function, which were not previously considered central to allergic rhinitis pathogenesis.^[4]

The identification of genetic variants associated with allergic disease, particularly when combined with information on age of onset, opens new avenues for developing advanced prevention strategies.^[8] A deeper understanding of genetic predispositions could enable the early identification of individuals at high risk, facilitating targeted preventive measures before symptom manifestation. Moreover, the application of computational modeling alongside GWAS is enhancing the understanding of how demographic and genetic factors influence the trajectories of the “allergic march,” which can lead to improved identification, diagnosis, and treatment for at-risk patient populations. ^[5]This integrated approach supports the development of more effective monitoring strategies and interventions, paving the way for a more proactive and genetically informed management of allergic rhinitis.

Frequently Asked Questions About Allergic Rhinitis

These questions address the most important and specific aspects of allergic rhinitis based on current genetic research.

---

1. My parents have hay fever. Will my kids definitely get it too?

Not necessarily “definitely,” but their risk is much higher. Genetic factors play a substantial role in allergic rhinitis susceptibility, and these risk factors can be passed down. While genetics increase the likelihood, environmental factors also contribute, so it’s not a guarantee.

2. Why do some people never get hay fever, no matter the pollen count?

It often comes down to their unique genetic makeup. Genome-wide association studies have identified many genetic risk loci and pathways that influence who develops allergic rhinitis. Some individuals simply have a different combination of these genetic factors that makes them less susceptible to environmental allergens.

3. I’m African American – does my heritage affect my allergy risk?

Yes, it can. Research has identified susceptibility loci that are specific to certain ethnicities. For example, a genetic variant in the LINC00299gene, associated with progression from atopic dermatitis to asthma, has been found to be enriched in individuals of African American ancestry.

4. Is my childhood eczema why I have hay fever now?

There’s a strong genetic link between them, suggesting a connection. Allergic rhinitis often co-occurs with other allergic diseases like eczema, and studies show they share a significant genetic architecture. This shared genetic basis contributes to the “allergic march,” where one allergic condition may precede others over a person’s lifetime.

5. Could a DNA test tell me why I get such bad allergies?

A DNA test could provide valuable insights into your genetic predisposition. Genome-wide association studies have identified many genetic variants associated with allergic rhinitis. While it won’t give a complete picture, understanding your specific genetic risk factors could help explain your susceptibility and severity.

6. Why are my allergies so severe compared to my friends’?

Your individual genetic makeup likely plays a significant role in the severity of your allergic rhinitis. Specific genetic variants, known as expression single nucleotide polymorphisms (eSNPs), have been linked to both gene expression and allergic rhinitis, influencing how your immune system responds to allergens. These subtle genetic differences can lead to varying symptom severity among individuals.

7. Can I really ‘outrun’ my family’s allergy history?

While genetics play a substantial role in your susceptibility, lifestyle and environmental factors also contribute. Understanding your genetic risk factors is crucial, but managing your environment and seeking appropriate medical care can help mitigate symptoms. Genetics influence your predisposition, but they are not your sole destiny.

8. Could something deep inside my cells be causing my allergies?

Yes, absolutely. Beyond the immune system’s external response, research has implicated mitochondrial pathways within your cells in the pathogenesis of allergic rhinitis. This suggests that fundamental cellular processes and energy production could also contribute to how your body reacts to allergens.

9. If I have asthma, does that make my hay fever different?

It’s possible. Allergic rhinitis with concurrent asthma may represent a distinct subphenotype compared to allergic rhinitis without asthma. There’s a strong pathogenetic link and shared genetic architecture between upper airway diseases like allergic rhinitis and lower airway diseases like asthma.

10. Will knowing my genes help me get better allergy treatment?

Potentially, yes. Identifying genetic risk factors is crucial for advancing our understanding of disease mechanisms. This knowledge could lead to the development of more personalized and effective prevention and treatment strategies tailored to your specific genetic profile, improving patient outcomes.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Kim, J. W. et al. “Genome-wide Association Study of Susceptibility Loci for Self-Reported Atopic Dermatitis and Allergic Rhinitis in the Korean Population.”Ann Dermatol (2024): Published online Feb 8, 2024.

[2] Waage J, Standl M, Curtin JA, Jessen LE, Thorsen J, Tian C, et al. Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. Nat Genet 2018;50:1072-80.

[3] Saarentaus, E. C. et al. “Inflammatory and infectious upper respiratory diseases associate with 41 genomic loci and type 2 inflammation.” Nat Commun, vol. 14 (2023): 264.

[4] Bunyavanich, S. “Integrated genome-wide association, coexpression network, and expression single nucleotide polymorphism analysis identifies novel pathway in allergic rhinitis.”BMC Medical Genomics, vol. 7, no. 1, 2014, p. 48.

[5] Gabryszewski SJ, et al. Unsupervised Modeling and Genome-Wide Association Identify Novel Features of Allergic March Trajectories. J Allergy Clin Immunol 2020;146:1354-1365.e7.

[6] Zhu Z, Lee PH, Chaffin MD, Chung W, Loh PR, Lu Q, et al. A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases. Nat Genet 2018;50:857-64.

[7] Johansson, A. et al. “Genome-wide association analysis of 350 000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema.”Hum Mol Genet, vol. 29, no. 1, 2019, pp. 119-132.

[8] Ferreira, M. A. R. et al. “Age-of-onset information helps identify 76 genetic variants associated with allergic disease.”PLoS Genet, vol. 16, no. 6 (2020): e1008725.

[9] Bønnelykke K, Matheson MC, Pers TH, Granell R, Strachan DP, Alves AC, et al. Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization. Nat Genet 2013;45:902-6.

[10] Morii W, et al. A genome-wide association study for allergen component sensitizations identifies allergen component-specific and allergen protein group-specific associations. J Allergy Clin Immunol Glob 2023;2:100099.

[11] Ferreira MA. Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype. J Allergy Clin Immunol 2013;133:1710-1718.e11.

[12] Pariente, P. D., LePen, C., Los, F., & Bousquet, J. “Quality-of-life outcomes and the use of antihistamines in a French national population-based sample of patients with perennial rhinitis.”Pharmacoeconomics, vol. 12, 1997, pp. 585–95.

[13] Ferreira, M. A. et al. “Eleven loci with new reproducible genetic associations with allergic disease risk.”J Allergy Clin Immunol, 2018.

[14] Noguchi, E., et al. “HLA-DQ and RBFOX1 as susceptibility genes for an outbreak of hydrolyzed wheat allergy.”J Allergy Clin Immunol, vol. 144, 2019, pp. 1354-63.

[15] Bonnelykke, K. et al. “Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization.”Nat Genet, vol. 45, 2013, pp. 902-6.

[16] Ramasamy, A., et al. “A genome-wide meta-analysis of genetic variants associated with allergic rhinitis and grass sensitization and their interaction with birth order.”J Allergy Clin Immunol, vol. 128, 2011, pp. 996-1005.

[17] Mohammadnejad, A. et al. “A case-only genome-wide association study on gene-sex interaction in allergic rhinitis.”Ann Allergy Asthma Immunol (2018).

[18] Sugita, K., and K. Kabashima. “Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagus, and inflammatory bowel diseases.”Journal of Leukocyte Biology, vol. 107, 2020, pp. 749–762.

[19] Guerra, S., et al. “Rhinitis as an independent risk factor for adult-onset asthma.”J Allergy Clin Immunol, vol. 109, no. 3, 2002, pp. 419-25. PMID: 11897985.

[20] Burgess, J. A., et al. “Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study.”J Allergy Clin Immunol, vol. 120, no. 4, 2007, pp. 863-9. PMID: 17825896.

[21] Braunstahl, G.-J. “The unified immune system: Respiratory tract–nasobronchial interaction mechanisms in allergic airway disease.”J Allergy Clin Immunol, vol. 115, no. 1, 2005, pp. 142-8.

[22] Leynaert, B., et al. “Epidemiologic evidence for asthma and rhinitis comorbidity.”J Allergy Clin Immunol, vol. 106, no. 5 Suppl, 2000, pp. S201-5. PMID: 11080732.